

# Martin Unverdorben

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4120252/publications.pdf>

Version: 2024-02-01

13  
papers

275  
citations

1478505

6  
h-index

1372567

10  
g-index

14  
all docs

14  
docs citations

14  
times ranked

354  
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. <i>New England Journal of Medicine</i> , 2021, 385, 2150-2160.	27.0	144
2	Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial. <i>American Heart Journal</i> , 2018, 205, 63-69.	2.7	62
3	Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study. <i>Clinical Cardiology</i> , 2020, 43, 769-780.	1.8	20
4	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019, 42, 1147-1154.	1.8	16
5	Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study. <i>International Journal of Cardiology</i> , 2022, 346, 93-99.	1.7	11
6	Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)—Trial design. <i>Clinical Cardiology</i> , 2018, 41, 1123-1129.	1.8	9
7	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 485-490.	1.4	6
8	Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study. <i>European Heart Journal</i> , 2020, 41, .	2.2	3
9	Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 504.	1.7	2
10	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 5337.	2.4	2
11	Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. <i>Blood</i> , 2021, 138, 3024-3024.	1.4	0
12	Periprocedural Interruption of Edoxaban in Real World Setting: Results from the Emit AF/VTE Study. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
13	Management of edoxaban in patients undergoing multiple procedures: a subanalysis of the EMIT-AF/VTE program. <i>Europace</i> , 2022, 24, .	1.7	0